Uniqure, Chiesi Ink $40M Deal In Europe, China for Glybera
By Cormac Sheridan
Wednesday, July 10, 2013
Gene therapy pioneer Uniqure BV is banking €31 million (US$39.6 million) through a commercialization and equity deal with Chiesi Famaceutici SpA that involves European and Chinese rights to its approved gene therapy product, Glybera (alipogene tiparvovec), as well as rights in Europe and several other territories to its hemophilia B gene therapy program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.